Starton Therapeutics to Present at Biotech Showcase 2026
Company Will Also Host 1x1 Investor Meetings at the 15th Annual LifeSci…
Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer
AGOURA HILLS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc.…
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
December 12, 2025 16:30 ET | Source: Zevra Therapeutics CELEBRATION, Fla., Dec.…
Aukera Therapeutics Comes Out of Stealth
BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Aukera Therapeutics, a preclinical-stage…
Indivumed and University of Rochester Medical Center expand collaboration for patient-centric discovery of novel therapeutics
Two leading entities in cancer research pledge scientific collaboration to advance precision…
Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025
– New findings demonstrate a 72% HI-E response rate at Week 16…
TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
December 06, 2025 17:30 ET | Source: TScan Therapeutics, Inc. Treatment arm…
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc. ― Clear…
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected…
Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company…
